The processes involved with ␤-amyloid (A␤) degradation and clearance in human brain are not well understood. We hypothesized that the distribution of oxidatively modified A␤, as determined by an affinity-purified antibody in the entorhinal and frontal cortices of Alzheimer's disease (AD), Down syndrome (DS), nondemented elderly control cases, and canine brain, would provide insight into the mechanisms of A␤ accumulation. Based upon plaque counts, oxidized A␤ was present within 46 -48% of diffuse and primitive plaques and 98% of cored plaques. Dense punctate deposits of oxidized A␤ were distributed throughout the neuropil in AD and DS brains but were also present within controls with mild neuropathology and isolated cognitive impairments. Confocal studies indicate that punctate oxidized A␤ deposits were within activated microglia. Oxidatively modified A␤ may reflect the efforts of microglial cells to take up and degrade A␤. Oxidative modification of A␤ may be an early event in A␤ pathogenesis and may be important for plaque biogenesis.
INTRODUCTION
Alzheimer's disease (AD) is associated with the progressive development of cognitive dysfunction and neuropathological accumulation of neurofibrillary tangles and senile plaques (SP) (Khachaturian, 1985; Morris et al., 1988; Mirra et al. 1991 ; The National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease, 1997). A major constituent of SP is the amyloid ␤ protein (A␤), which is a 39-to 42-amino acid peptide cleaved from a longer amyloid precursor protein (APP) (Glenner & Wong, 1984; Kang et al., 1987) . Understanding the mechanisms underlying the enhanced aggregation and accumulation of A␤ in the pathogenesis of AD is important because of evidence for several familial forms of AD linked to mutations on the APP gene, all of which result in the increased production of the more amyloidogenic and insoluble isoform A␤1-42 (reviewed by Selkoe, 1996) . Further, Down syndrome (DS) or trisomy 21 results in a gene dosage effect with A␤ deposition occurring as young as 12 years (Lemere et al., 1996) and with the inevitable development of AD neuropathology by the age of 40 years (Wisniewski et al., 1978; Mann, 1988; Lai & Williams, 1989) . In addition to genetic evidence, other studies demonstrate the neurotoxicity of A␤ in vitro and in vivo (reviewed by Yankner, 1996) . Thus, the accumulation of senile plaques may be a result of the overexpression of APP, cleavage to A␤, which leads to enhanced aggregation or an inability to degrade and clear existing deposits.
A␤ deposition and accumulation are dependent upon two opposing processes: production and degra-
